Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
Background: Postmenopausal osteoporosis is characterized by osteoclast differentiation and bone loss. Tangeretin (TGN) is a natural product that possesses multiple pharmacological properties. However, its specific function in postmenopausal osteoporosis deserves further exploration. Methods: The in...
Saved in:
| Main Authors: | Tengfei Wu, Fang Wang, Changqing Ai, Li Li, Fan Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | Regenerative Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352320425000951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quality use of medicines: The postmenopausal woman with osteoporosis
by: Andy Gray, et al.
Published: (2003-05-01) -
Narirutin mitigates inflammatory arthritis and osteoporosis through modulating macrophage phenotype and osteoclastogenesis
by: Qing Wang, et al.
Published: (2025-09-01) -
OSTEOPOROSIS: ASSESSMENT OF A RISK FOR RECURRENT LOW-TRAUMA FRACTURES IN POSTMENOPAUSAL WOMEN
by: O. V. Dobrovolskaya, et al.
Published: (2016-03-01) -
Pathogenetic treatment with strontium ranelate in women with postmenopausal osteoporosis
by: Olga Borisovna Yershova
Published: (2010-12-01) -
The Comparison of Effects of Alendronate and Raloxifene Treatment in Postmenopausal Women with Osteoporosis - Original Investigation
by: Gülcan Gürer, et al.
Published: (2006-03-01)